STUDY POPULATION. One hundred twenty children 7 to 11 years of age were enrolled and assigned to 4 different groups: (1) obese asthmatic children, (2) atopic nonobese asthmatic children, (3) obese nonasthmatic children, and (4) nonobese, nonasthmatic children.
METHODS. All children performed pulmonary function testing, and anthropometric data were obtained. Asthma severity was classified based on daytime and nighttime symptoms, exercise limitation, and albuterol use (parental report). Blood was obtained for serum cytokines, T-cell responses to mitogen and allergen, and phenotyping.
RESULTS. Serum interleukin (IL)-4 and IL-13 levels were higher among nonobese asthmatic children, consistent with a T-helper (Th)2 phenotype of atopic asthma. In contrast, obese asthmatic children had lower levels of IL-13 and higher levels of tumor necrosis factor-a and IL-6, consistent with a Th1 phenotype. Obese asthmatic children had higher Th1 response to phorbol 12-myristate 13-acetate and tetanus and lower Th2 responses to phorbol 12-myristate 13-acetate and dust mite allergen compared to nonobese asthmatic children. The Th pattern did not differ between obese asthmatic children and obese nonasthmatic children. Spirometric data were within the normal range in all 4 study groups. However, the forced expiratory volume in 1 second/forced vital capacity ratio was lower in obese asthmatic children compared with the other asthmatic children.
CONCLUSIONS. Obese asthmatic children exhibited a Th1 polarization in contrast to the Th2 polarization seen in atopic childhood asthma. The Th1 response did not differ between obese asthmatic children and obese nonasthmatic children. This suggests that obese asthmatic children exhibit a systemic Th1 polarization that may be modulated more by obesity and less by their asthma.
REVIEWER COMMENTS. Obesity-associated asthma has been proposed as a distinct entity, and this is one of the first studies to try to characterize the underlying mechanism and compare them to atopic asthma in children. Given the obesity epidemic facing our children, understanding these differences can be helpful in treating this population. Given the fact that the inflammation seems to be influenced more by the obesity itself, addressing the obesity may be a major therapeutic intervention to treat obese asthmatic patients. METHODS. Asthma status and medications were determined from medical records and self-administered questionnaires, and glycemic control was assessed from hemoglobin A1c measured during study visits.
RESULTS. The prevalence of asthma in all children with diabetes was 10.9% (95% confidence interval [CI], 9.6%-12.3%).
The prevalence was 10% (95% CI, 8.6%-11.4%) among children with type 1 and 16.1% (95% CI, 12.0%-20.2%) among children with type 2 diabetes and differed by race/ ethnicity. Among children with type 1 diabetes, higher mean A1c levels were observed in asthmatics versus nonasthmatics after adjustment for age, gender, race/ ethnicity, and BMI (7.77% vs 7.49%, P 5 .034). Youth with asthma were more likely to have poor glycemic control, particularly those with type 1 diabetes whose asthma was not treated with routine pharmacotherapy.
CONCLUSIONS. The prevalence of asthma may be elevated in children with diabetes relative to the general US population. In children with type 1 diabetes, asthma is associated with poor glycemic control, especially if asthma is not treated with antiinflammatory medications.
including obesity and both asthma and diabetes. The association between type 2 diabetes and asthma is not surprising as a high proportion of youth were overweight or obese (90.6%) and the linkage between asthma and increased BMI is well described in many studies. It is interesting to note that children whose asthma was treated with leukotriene modifiers, alone or in combination with inhaled corticosteroids or rescue inhalers, had the lowest prevalence of poor glycemic control; in fact, 72% had good glycemic control. The authors speculate that this could be because leukotriene synthesis or receptor blockers may help reduce the systemic inflammation present in both obesity and diabetes as well the direct effect on ameliorating airway inflammation. RESULTS. DNA hypomethylation was associated with increased risk for persistent wheezing in both studies, although only 1 of the 2 was statistically significant (Menorca: odds ratio 1.13, 95% confidence interval 0.99-1.29, P 5 .077; Sabadell: odds ratio 1.16, 95% confidence interval 1.03-1.37, P 5 .017). Higher levels of dichlorodiphenyldichloroethylene were associated with hypomethylation of ALOX12 in the Menorca study (P 5 .033), but not the Sabadell study (P 5 .377). Level of methylation at ALOX12 was strongly influenced by polymorphisms in the gene.
CONCLUSIONS. DNA hypomethylation at ALOX12 was associated with a higher risk of persistent wheezing. This may be an epigenetic biomarker that predicts increased likelihood of persistent wheezing in childhood.
REVIEWER COMMENTS. This study adds to the knowledge that genes and the environment combine to influence asthma phenotype. In this case, ALOX12, a gene associated with airway inflammation, appears to exhibit variation in methylation, not based on genotype alone, but possibly on environmental factors, including prenatal pollutant exposure. Therefore, the degree of methylation at certain CpG sites on this gene may be an early biomarker that helps to predict wheezing phenotype. METHODS. Microarray-derived genotypes of Australian asthmatic subjects and controls underwent a genomewide association study to produce asthma candidate loci. Meta-analysis using unique adult Australian and previously published GABRIEL genotypes prioritized candidate novel genetic loci. The prioritized, novel genetic loci endured replication analysis via 4 individual cohorts and a combined meta-analysis. A genomic phenotype prediction model for asthma was produced and subsequently tested. Secondary analysis considered asthma and other immune disease associations.
RESULTS. Two novel loci were significantly associated with asthma risk. The interleukin-6 receptor (IL6R) loci on chromosome 1q21.3 associated more significantly (odds ratio [OR] 5 1.09, P 5 .0033) than the indeterminate loci (rs7130588) at chromosome 11q13.5 (OR 5 1.07, P 5 .328) in the replication cohorts. However, when considering all available data, 1q21.3 and 11q13.5 both demonstrated very significant asthma association (OR 5 1.09, P 5 2.3 3 10 28 and OR 5 1.09, P 5 1.8 3 10 28 , respectively). Secondary analyses of 11q13.5 revealed an association with atopy and no asthma risk association
